Sherin Abdel-Meguid

Dr. Abdel-Meguid has extensive experience in drug discovery. He built and managed a number of successful departments and drug discovery programs. He founded Shifa Biomedical Corporation (Shifa), a company dedicated to the treatment of cardiovascular diseases. He also founded ProXyChem, a company focused on providing drug discovery solutions to the biotech and pharmaceutical sector. Prior to this, he was Chief Scientific Officer and Co-Founder of Suntory Pharmaceutical Research Laboratories (SPRL), a structure-based drug discovery company dedicated to the treatment of cardiovascular and immune disorders. Before the formation of SPRL, he was Worldwide Director of Structural Biology and Director of Macromolecular Sciences at SmithKline Beecham (SB), now Glaxo SmithKline (GSK). He also served as Director of several therapeutic programs. Prior to SB, he was head of Biophysical Sciences and Protein Engineering at Monsanto. He has a PhD in Physical Chemistry and MS and BS in Biochemistry.